Centuri Holdings (CTRI) director reports RSU vesting and new equity grant

Centuri Holdings (NYSE: CTRI) reported Q2 2026 revenue of $962.0 million, up 33% year over year, and adjusted net income of $24.4 million, up 44%. The company booked nearly $850 million in Q2 and $2.2 billion year to date, with a $16 billion opportunity pipeline. It also completed the JJ White acquisition and raised full-year 2026 guidance, according to the company.

Centuri Holdings, Inc. (CTRI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Contacts: For Centuri investors, contact: For Centuri media information, contact: Nate Tetlow Jennifer Russo (480) 851-8426 (602) 781-6958 Ntetlow@centuri.com JRusso@Centuri.com FOR IMMEDIATE RELEASE August 4, 2026 CENTURI REPORTS SECOND QUARTER 2026 RE

Michael Burry sold his stake in Alibaba (BABA), calling its shares overvalued and objecting to its $10.2B share sale for AI funding. He reinvested in JD.com (JD), citing easing competition in China's delivery market. Alibaba's hedge fund holdings decreased slightly, while JD.com's saw a minor increase.

The US approved a $5 billion arms sale to Saudi Arabia, including 10,000 guidance kits and bombs. The State Department cleared the deal, citing national security interests. Boeing is the principal contractor. This follows escalating tensions between the US and Iran, with recent strikes and retaliations.

John Ternus became Apple's CEO on September 1, 2026. He will oversee his first product event on September 9, featuring a foldable iPhone, new Apple Watches, and the launch of iOS 27 with Google's Gemini AI. Ternus, a hardware engineer, faces challenges in AI development and investor skepticism about Apple's AI strategy. Apple reported record revenue of $109.4 billion in Q2 2026 but saw a 9.4% stock drop due to weak guidance and AI concerns.

Novartis and Ionis Pharmaceuticals reported that their experimental heart drug, pelacarsen, failed to reduce the risk of major heart attacks and strokes in a late-stage trial. The drug, targeting genetically inherited cholesterol Lp(a), lowered Lp(a) levels but did not meet its primary endpoint. Novartis shares fell 5%, and Ionis shares dropped 12% in aftermarket trading. The companies plan to present full trial data at an upcoming medical congress.